Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study.

Two individuals (patients 7 and 8) received immune checkpoint inhibition (ICI) prior to BMT; patient 7 received anti-CTLA-4 and anti-PD-1 combination therapy, and patient 8 received anti-PD-L1 and interferon combination therapy. From 2003 to 2020, eight patients received partially mismatched donor BMT for relapsed/refractory MF/SS. Seven patients received grafts from HLA-haploidentical related donors. Primary cutaneous T-cell lymphomas (CTCLs), a heterogeneous group of extranodal non-Hodgkin lymphomas involving the skin, are dominated by two main subtypes: mycosis fungoides (MF) and Sézary syndrome (SS) [[1]]. An eighth patient (patient 5) experienced graft failure after double unrelated donor umbilical cord blood transplantation and within 6 months underwent partially mismatched unrelated donor BMT. [Extracted from the article]